Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 209 publications
Mutated p53 results in altered type I interferon pathway expression and signaling in endometrial cancer.
Journal: Gynecologic oncology
Published: June 11, 2026
Associations between molecular classification and response to intra-uterine levonorgestrel device therapy in patients with medically managed endometrial cancer and endometrial intra-epithelial neoplasia: a multi-center Endometrial Cancer Molecularly Targeted Therapy (ECMT2) Consortium study.
Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Published: April 08, 2026
Molecular classification and association with survival outcomes in high-intermediate and high-risk early-stage endometrial cancers: Ancillary analysis of GOG-0249.
Journal: Gynecologic oncology
Published: March 19, 2026
Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings.
Journal: Expert opinion on investigational drugs
Published: February 26, 2026
MLH1 promoter hypermethylation and associations with survival outcomes: A real-world endometrial cancer molecularly targeted therapy consortium cohort study.
Journal: Gynecologic oncology
Published: February 15, 2026
Correlation of patient reported outcomes and physical exam screening for pelvic floor dysfunction: An opportunity for improved quality of life during chemoradiotherapy for cervical cancer.
Journal: Gynecologic oncology reports
Published: February 10, 2026
Correction: GAS6/AXL Inhibition Enhances Ovarian Cancer Sensitivity to Chemotherapy and PARP Inhibition through Increased DNA Damage and Enhanced Replication Stress.
Journal: Molecular cancer research : MCR
Published: January 20, 2026
The combination of avutometinib and defactinib in treating recurrent low-grade serous ovarian cancer: a plain language summary of the Phase II clinical trial ENGOT-OV60/GOG-3052/RAMP 201.
Journal: Future oncology (London, England)
Published: December 12, 2025
Corrigendum to "OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer" [Gynecol Oncol 2025 Jun 197 182-191].
Journal: Gynecologic oncology
Published: November 07, 2025
Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: October 13, 2025
Targeting RAD52 overcomes PARP inhibitor resistance in preclinical Brca2-deficient ovarian cancer model.
Journal: bioRxiv : the preprint server for biology
Published: October 03, 2025
Last Updated: 09/26/2026